Merrill retains Actelion at neutral

Actelion was retained by Merrill Lynch analyst Erica Whittaker at a neutral rating after a competitor released data on a phase 3 trial for ambrisentan, which showed not only better safety than the company's Tracleer, but also superior efficacy. That drug is expected to treat 40% of new PAH patients and Tracleer 15% with ambrisentan sales exceeding Tracleer sales by 2012. There is further risk to Tracleer sales if ambrisentan receives fast-track regulatory review. Shares of the Basel, Switzerland, biopharmaceutical company were up CHF 3.30, or 3.12%, at CHF 109.00 on volume of 1,355,160 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.